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Summary
Background: This study was designed to evaluate the factors that affect myocar-
dial salvage after percutaneous coronary intervention (PCI) in patients with acute
myocardial infarction (AMI).
Methods and results: One hundred and eighty-three patients with AMI who had
undergone successful PCI were recruited for this study. Patients underwent 99mTc-
pyrophosphate single photon emission computed tomography (SPECT) on the third
day and 99mTc-MIBI SPECT on the sixth day after admission. In the 20 SPECT seg-
ments, the summed defect score (TDS) and extent score (ES) of AMI segments were
determined and the percentage of the salvaged myocardium was calculated based
on the TDS and ES. We performed multivariate analysis to evaluate factors that can
affect myocardial salvage. Multivariate analysis was performed among the value of
myocardial salvage rate and the 15 clinical variables. Administration of nicorandil
(p = 0.006), prodromal angina (p < 0.001), and high TIMI grade (p < 0.001) had signiﬁ-
cant positive correlation to myocardial salvage rate. Use of a distal protection device
had a signiﬁcant negative correlation with myocardial salvage rate (p = 0.006).
Conclusions: The presence of high TIMI grade before PCI and prodromal angina are
very important for salvaging myocardium. Furthermore, administration of nicorandil
is important in salvaging m
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as improved prognosis in patients with acute
yocardial infarction (AMI) [1,2]. In animal models
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of AMI, myocardium at risk, collateral ﬂow, and
duration of coronary occlusion are important
determinants of ﬁnal infarct size [3—7]. These
three variables have been shown by Christian et
al. [8] to be important determinants of infarct
size in human subjects. However, some patients
continue to have deterioration in cardiac func-
tion after primary PCI, which is thought to be
due to reperfusion injury [9,10]. Restoration of
blood ﬂow to cardiac cells damaged by ischemia
may result in irreversible injury to these cells.
Therefore, prevention of reperfusion injury con-
tributes to improvement in the long-term prognosis
and chronic cardiac function in patients with
AMI.
Nicorandil is a hybrid agent combining adeno-
sine triphosphate (ATP)-sensitive K+ (KATP)
channel opener and nicotinamide nitrate, and
has been shown to decrease infarct size and
the incidence of arrhythmias after coronary
artery ligation and reperfusion in experimental
animals [11,12]. Recent clinical studies have
shown that intravenous administration of nico-
randil in conjugation with reperfusion therapy
in patients with AMI preserves microvascular
integrity, decreases the incidence of no-reﬂow
phenomenon, and improves myocardial via-
bility and functional and clinical outcome
[13—16].
This study was designed to evaluate the factors
affecting myocardial salvage after percutaneous
intervention in patients with initial acute myocar-
dial infarction.
Methods
Patients
One hundred and eighty-three patients with AMI
who had undergone successful PCI with or with-
out stenting within 24 h of the onset of symptoms
were recruited to this study. A diagnosis of AMI
was based on the following criteria: acute chest
pain lasting >30min; serum creatine kinase activity
>500 IU; and development of abnormal electrocar-
diolographic Q waves. Prodromal angina (ischemic
preconditioning) was deﬁned as a brief episode
of typical chest pain lasting <30min within 24 h
before the onset of AMI. Patients who fulﬁlled the
following criteria were included in the statistical
analysis: successful PCI with or without coronary
stenting with angiographic conﬁrmation of <25%
residual stenosis; no signiﬁcant stenosis in other
vessels; good image quality for all radiotracer stud-
ies.
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tudy protocol
n the patients receiving nicorandil, we injected
icorandil (4mg; Sigmart, Chugai, Tokyo) intra-
enously, and maintained a continuous infusion
t 4mg/h over a 24-h period, which was started
efore PCI. Then we injected nicorandil (2mg) into
he coronary artery just after reperfusion. Other
reatments were the same between those patients
eceiving and those not receiving nicorandil. All
atients underwent cardiac catheterization follow-
ng the injection of 5000U of heparin. Following
njection of 2.5mg of isosorbide into the coronary
rtery, we performed coronary angiography (CAG)
nd PCI. Heparin administration was continued for 1
r 2 days. At the same time, nitroglycerin was con-
inuously infused at 1.5mg/h over a period of 1 or
days. All patients were maintained on a regimen
f aspirin and ticlopidine.
The scintigraphic studies used included resting
9mTc-pyrophosphate (PYP) single photon emission
omputed tomography (SPECT) on the third day,
nd resting 99mTc-MIBI SPECT on the sixth day
fter admission. All scintigraphic studies were per-
ormed after a 12-h overnight fast in the absence
f antianginal medication.
All patients provided informed consent in accor-
ance with the guidelines set by our hospital’ s
uman clinical study committee.
99mTc-PYP SPECT. Each patient received 740 MBq
f 99mTc-PYP intravenously. All patients underwent
yocardial imaging 2 h later.
99mTc-MIBI SPECT. The 99mTc-MIBI was obtained
ommercially (Nihon MediPhysics, Chiba, Japan).
he patients received an intravenous injection of
40 MBq of 99mTc-MIBI while sitting upright. Gated
PECT images were acquired 30min after injection.
he RR interval was divided into 16 subintervals for
ated SPECT acquisition.
Myocardial SPECT imaging. Myocardial SPECT
maging was performed using a PRISM3000 (PICKER,
leveland, OH, USA) three-headed SPECT system
ith low-energy, all-purpose resolution, parallel-
ole collimators. The detector system was linked
o a dedicated nuclear medicine computer. A total
f 72 projection images were obtained over a 360◦
rc in 5◦ increments, with 55 s/view acquisitions
or 99mTc-PYP, and with 40 s/view acquisitions for
9mTc-MIBI. The energy discriminator was centered
n 140 keV for 99mTc-PYP and 99mTc-MIBI with a 15%
indow. Data were recorded in 64× 64 matrices
o a magnetic disc. Butterworth (order: 8, cutoff
requency: 0.25 cycle/pixel) and ramp ﬁlters were
sed to reconstruct transaxial tomographic images
rom each acquisition. Short- and long-axis slices
5.4-mm thick) were generated.
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Analysis of SPECT. For each study, SPECT analysis
as based on one vertical long-axis slice and three
hort-axis slices. In each patient, corresponding
ertical long- and short-axis tomograms from the
9mTc-PYP and 99mTc-MIBI SPECT image sets were
ligned. Additionally, one vertical long-axis slice
nd three short-axis views from the apical, mid-
le, and basal ventricular levels were chosen for
omparison. The vertical long-axis slice was used
o evaluate the apical region, which was divided
nto two segments, while each short-axis slice was
ivided into six segments (Fig. 1). All SPECT images
ere analyzed by two experienced observers with
o knowledge of the patient’s clinical history.
emiquantitative visual analysis was performed
y assigning regional tracer uptake activity by a
our-point scoring system (defect score): 3 = absent
ptake; 2 = signiﬁcantly reduced uptake; 1 =mildly
educed uptake; 0 = normal uptake. Disagreements
n interpretation were resolved by consensus. We
eﬁned the number of segments in which the 99mTc-
YP accumulated as the extent score (ES). We
eﬁned the sum of defect scores in the infracted
rea in which the 99mTc-PYP accumulated as the
otal defect score (TDS).
The percentage salvaged myocardium was
alculated by the following formula: (3× ES-
DS)/(3× ES)× 100 (%).
We performed multivariate analysis to evalu-
te factors that can affect myocardial salvage. We
eﬁned myocardial salvage rate as dependent vari-
ble and 15 variables as independent variables.
ndependent variables included age, gender, admin-
stration of nicorandil, prodromal angina (ischemic
reconditioning), onset to recanalization time, use
f distal protection device, the grade of collat-
ral ﬂow using the Rentrop grading scale (0 = none;
= ﬁling of side branches of the artery to be dilated
ia collateral channels without visualization of the
picardial segment; 2 = partial ﬁlling of the epicar-
ial segment via collateral channels; 3 = complete
lling of the epicardial segment of the artery
ilated via collateral channels) just before reper-
c
w
t
(
mSPECT imaging.
usion, thrombolysis in myocardial infarction (TIMI)
rade ﬂow just before reperfusion, coronary risk
actors, and culprit lesions.
tatistical analysis
ata are expressed as mean± S.D. for continuous
ariables, and as numbers (percentage) for cat-
gorical variables. One-way analysis of variance
ANOVA) was used to compare the data among the 3
r 4 groups. Tukey’s test was used for multiple com-
arisons of individual groups. Pearson’s correlation
oefﬁcient analyses were used to examine the rela-
ionship between the value of myocardial salvage
ate and clinical values. Multiple regression analy-
is was performed among the values of myocardial
alvage rate and the clinical values. A p-value <0.05
as considered statistically signiﬁcant. All statisti-
al analyses were performed using SPSS software
SPSS Inc., IL, USA).
esults
atient characteristics are summarized in Table 1.
he salvage rate was signiﬁcantly higher in
atients with prodromal angina than without pro-
romal angina (Fig. 2: 60.2± 24.5 vs. 41.8± 25.2,
= 0.002). The salvage rate was signiﬁcantly
igher in patients receiving nicorandil than in
hose not receiving nicorandil (Fig. 3: 58.0± 24.9
s. 48.8± 25.5, p = 0.01). The salvage rate was
8.3± 24.3 in TIMI 0, 49.2± 32.7 in TIMI 1,
2.2± 25.9 in TIMI 2, 70.8± 19.3 in TIMI 3, showing
signiﬁcant difference among the 4 groups (Fig. 4:
< 0.001). Multiple comparisons using Tukey’s test
evealed a signiﬁcantly higher salvage rate in TIMI
compared with TIMI 0 (p < 0.001), and TIMI 2ompared with TIMI 0 (p < 0.05). The salvage rate
as signiﬁcantly lower in patients using distal pro-
ection than in those not using distal protection
42.7± 25.7 vs. 55.5± 24.9, p = 0.007). Further-
ore, in multivariate analysis, administration of
272 J. Murakami et al.
Table 1 Clinical characteristics of the study patients
Characteristics Values
Age (year) 63± 11
Male 139 (76)
Maximum CPK (IU/l) 3498± 2474
Administration of nicorandil 81(44)
Prodromal angina 79 (43)
Onset to recanalization time (h) 6.7± 7.9
Use of distal protection device 36 (20)
Grade of collateral ﬂow (0/1/2/3) 102/33/40/8
TIMI grade (0/1/2/3) 127/8/26/22
Coronary risk factor
Diabetes 58 (32)
Dyslipidemia 74 (40)
Hypertension 105 (57)
Smoking 103 (56)
Culprit lesion (LAD/LCX/RCA) 114/19/50
Data are presented as the mean± S.D. or number (%). CPK,
creatine kinase; TIMI, thrombolysis in myocardial infarction;
LAD, left anterior descending artery; LCX, left circumﬂex
artery; and RCA, right coronary artery.
Figure 2 Comparison between salvage rate with prodro-
mal angina and without prodromal angina.
Figure 3 Comparison between salvage rate with
nicorandil administration and without nicorandil admin-
istration.
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mFigure 4 Salvage rate according to TIMI grade.
icorandil, prodromal angina, and high TIMI grade
ad signiﬁcant positive correlations with myocar-
ial salvage rate. Use of a distal protection device
ad a signiﬁcant negative correlation with myocar-
ial salvage rate (Table 2).
iscussion
eperfusion of the ischemic myocardium by PCI
educes the size of infarct and improves left
entricular function. However, in some patients,
eperfusion adversely leads to tissue damage,
hich is known as reperfusion injury [10]. The
resent study demonstrated that the presence of
igh TIMI grade before PCI and ischemic precon-
itioning were the most important variables for
yocardial salvage. Furthermore, administration of
Table 2 Multiple regression analysis with the value
of salvage rate as the dependent variable
Variables -Coefﬁcient p-Value
Age −0.127 0.059
Male −0.035 0.602
Nicorandil 0.183 0.006
Prodromal angina 0.271 <0.001
Recanalization time −0.020 0.760
Distal protection −0.185 0.006
Grade of collateral ﬂow 0.137 0.052
TIMI grade 0.285 <0.001
Diabetes −0.065 0.332
Dyslipidemia 0.060 0.067
Hypertension −0.036 0.594
Smoking −0.058 0.399
LAD 0.071 0.292
RCA 0.002 0.971
LCX −0.117 0.082
TIMI, thrombolysis in myocardial infarction; LAD, left ante-
rior descending artery; RCA, right coronary artery; and LCX,
left circumﬂex artery.
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tmportant factors for salvaging myocardium in AMI
icorandil was important in salvaging myocardium
n patients with AMI. Stone et al. [17] reported
hat patients undergoing primary PCI in whom TIMI-
ﬂow is present before angioplasty have clinical
nd angiographic evidence of greater myocardial
alvage, are less likely to develop complica-
ions related to left ventricular failure, and have
mproved early and late survival. Some studies have
hown that prodromal angina pectoris occurring
hortly before the onset of infarction is associ-
ted with reduced infarct size and improved left
entricular function. Ishihara et al. [18] concluded
hat prodromal angina has a beneﬁcial effect on
ong-term prognosis after infarction, suggesting
he presence of ischemic preconditioning. Experi-
ental studies have shown that brief episodes of
schemia shortly before prolonged coronary occlu-
ion reduce myocardial infarct size [19].
Nicorandil is a nicotinamide derivative with a
itrate moiety, which works like a nitrate and
t the same time opens KATP channels. Several
echanisms have been postulated to explain its
ardioprotective effects. Inhibition and reduction
f calcium inﬂow into myocytes may have car-
ioprotective effects in the ischemic heart and
ATP channel openers increase this effect [20].
nd nicorandil inhibits calcium ions from entering
ascular smooth muscle call by opening KATP chan-
els, and increases coronary blood ﬂow by dilating
esistance vessels (with a diameter <100m) that
annot be dilated by nitrates [21]. The dilation
f coronary microvessels by opening of KATP chan-
els appears to result in pharmacologic prevention
f slow ﬂow/no-reﬂow phenomenon. Furthermore,
icorandil inhibits inﬁltration of neutrophils into
issue and exhibits concentration-related anti-free
adical effects [22—24]. The inhibition of neutrophil
ctivation by nicorandil may be one mechanism by
hich it prevents microcirculatory dysfunction.
Multivariate analysis in the present study showed
hat clinical ischemic preconditioning (prodro-
al angina) is more effective than pharmacologic
schemic preconditioning (nicorandil administra-
ion) for myocardial salvage. Miyazawa et al. [25]
emonstrated that in patients without prodromal
ngina, the wall motion score in the patients
reated with nicorandil was signiﬁcantly better
han that of the patients without nicorandil treat-
ent. However, in patients with prodromal angina,
he difference was not signiﬁcant. Ishii et al.
26] suggested that left ventricular dysfunction
nd major cardiovascular events were prevented
t similar frequencies in patients with prodromal
ngina and patients with intravenous nicorandil
reatment and adding treatment with intravenous
icorandil to patients with prodromal angina had a
u
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p
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mall additional cardioprotective effect. Although
ood collateral ﬂow is reported to be effective in
ecreasing infarct size and improving left ventric-
lar ejection fraction, our results do not show a
orrelation between collateral ﬂow and myocar-
ial salvage. Toyama et al [27] demonstrated
icorandil’s effectiveness in patients with poor col-
ateral ﬂow and TIMI ﬂow and good ﬂow before
erfusion and hypothesized that the results seemed
o be induced by the preconditioning effect of nico-
andil operating as a KATP channel opener, which
as not inﬂuenced by collateral ﬂow or TIMI ﬂow
efore reperfusion.
While the efﬁcacy of nicorandil in salvaging
yocardium in AMI was demonstrated by several
tudies, the J-WIND study did not show the beneﬁ-
ial effects of nicorandil treatment compared with
uman atrial natriuretic peptide [28]. The size of
he dose was mentioned as one reason that nico-
andil treatment did not limit infarct size. Although
he dose of intravenous nicorandil administration
as similar to our dose, intracoronary injection of
icorandil was not performed in the J-WIND study.
e consider that intracoronary injection is also
mportant for presenting the direct effect of nico-
andil such as dilation of coronary microvessels and
nti-inﬂammatory response, which may contribute
o the attenuation of the no-reﬂow phenomenon.
ome studies reported the usefulness of intracoro-
ary nicorandil administration or combination of
icorandil drip infusion and intracoronary injection
14,16,25,29]. A further study about the method of
icorandil administration and the dose is necessary
o prove the effectiveness of nicorandil.
Distal embolization during PCI for AMI is asso-
iated with worse long-term outcomes. Therefore,
istal protection may prevent distal emboliza-
ion during PCI and improve clinical outcome
30,31]. However, some studies of distal protec-
ion have not found any improvement in clinical
utcome or infarct size [32,33]. Our study also
hows that distal protection does not reduce infarct
ize and has a negative correlation with myocar-
ial salvage. A recent large-scale, randomized
tudy, the EMERALD study [34], did not demon-
trate the usefulness of distal protection devices
n AMI patients and suggested some reasons for this
nding. First, the device may not have been efﬁ-
ient enough in aspirating liberated atherothrombic
ebris. Embolization may still have occurred at
he time of initial lesion crossing and/or into
nprotected proximal branches. Second, the addi-
ional delay to angioplasty required in the distal
rotection group may have played a role. Third,
ransmural infarction may similarly already be com-
leted with little chance for additional myocardial
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[
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[
[
[
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recovery in most patients reperfused after 3 h.
Fourth, while aspiration of emboli is not beneﬁ-
cial in a nonrestrictive ‘‘all comers’’ population,
selected subsets might exist in whom distal micro-
circulatory protection would be useful. In addition,
reperfusion using distal protection device may
cause further injury of the myocardium damaged
by infarction.
Limitations
This study has several limitations. First, data on
angina before AMI were based on patient inter-
views. Patients with impaired pain perception
would naturally provide inaccurate assessments of
prodromal angina. Second, we could not evalu-
ate similar culprit lesions because of the limited
number of patients. Third, we have not assessed
the most beneﬁcial dose or method of nico-
randil administration. Fourth, we used the formula:
(3× ES-TDS)/(3× ES)× 100 to calculate salvaged
myocardium. This was estimated as percentage
of salvaged myocardial uptake against maximal
uptake in infracted area at risk. This method is orig-
inal. However, it has not been reported before and
not established ever. Finally, this study consisted
of only 183 patients and was performed in a sin-
gle center. Therefore, there was the possibility of
selection bias and low statistical power.
Conclusion
The presence of high TIMI grade before PCI and pro-
dromal angina (preconditioning) are very important
for salvaging myocardium. Furthermore, admin-
istration of nicorandil is important in salvaging
myocardium in patients with acute myocardial
infarction.
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